IPDAS 5.0 Updates: Enhanced Standards for Patient Decision Aids

Written by The Life Science Feed Editorial Team · Published 1 July 2026 · Edited by Mara Voss

Patient decision aids (PDAs) are tools designed to help patients make informed healthcare decisions by providing evidence-based information on treatment options and their associated benefits and harms. The utility and effectiveness of these aids depend heavily on their quality and adherence to established standards. The International Patient Decision Aid Standards (IPDAS) Collaboration has released version 5.0, reflecting an updated, evidence-informed consensus process to enhance the development and evaluation of PDAs.

KEY TAKEAWAYS

- The Pivot: IPDAS version 5.0 expands its scope to include shared decision-making processes and addresses the evolving digital landscape for PDAs.
- The Data: The modified Delphi process involved 121 participants from 18 countries, achieving consensus on 60 quality criteria across 12 domains.
- The Action: Clinicians should seek out and recommend patient decision aids that explicitly state adherence to IPDAS 5.0 criteria, ensuring patients receive high-quality, evidence-based support for shared decision-making.

The International Patient Decision Aid Standards (IPDAS) Collaboration was established to improve the quality and effectiveness of patient decision aids (PDAs) by developing and promoting evidence-based standards for their content, development, and evaluation. PDAs are structured interventions designed to help patients participate in shared decision-making by clarifying treatment options, their potential outcomes, and patient values. The initial IPDAS framework, developed in 2005, provided a foundational set of criteria. Subsequent revisions aimed to refine these standards based on new research and practical experience. Version 5.0 represents a significant update, broadening the scope to address contemporary challenges and opportunities in shared decision-making, particularly concerning digital health and implementation.

What the study did

The development of IPDAS version 5.0 involved a comprehensive, evidence-informed consensus process, primarily utilizing a modified Delphi method. This iterative process engaged a diverse international panel of experts, including researchers, clinicians, patient advocates, and policymakers. The aim was to review existing IPDAS criteria, incorporate new evidence from systematic reviews on PDA effectiveness and implementation, and address emerging areas such as digital PDAs and the integration of PDAs into clinical workflows. The process began with an initial scoping review of literature to identify new evidence and potential areas for expansion or revision of the existing standards. This was

followed by multiple rounds of expert consultation and feedback.
A total of 121 participants from 18 countries contributed to the Delphi rounds. These participants were selected based on their expertise in shared decision-making, patient decision aids, health literacy, and clinical practice. The Delphi process involved presenting participants with proposed criteria and asking them to rate the importance and clarity of each criterion, as well as providing qualitative feedback. Criteria that did not achieve a predefined level of consensus (typically 70-80% agreement on importance) were revised and re-presented in subsequent rounds. This iterative refinement continued until consensus was reached on a final set of criteria.
The updated IPDAS 5.0 framework now comprises 60 quality criteria organized into 12 domains. These domains cover critical aspects of PDA development and evaluation, including content (e.g., accurate and balanced information on options, benefits, and harms), development process (e.g., systematic development, user testing), and implementation (e.g., integration into clinical practice, accessibility). Key additions and modifications in version 5.0 include enhanced criteria for digital PDAs, guidance on addressing health equity and cultural appropriateness, and a stronger emphasis on the process of shared decision-making itself, beyond just the PDA as a static tool. The revised standards also provide clearer guidance on how to assess the impact of PDAs on patient knowledge, values clarification, and decision quality. The consensus process ensured that the updated standards are both rigorous and practical, reflecting current best practices and anticipating future developments in the field.

Clinical Implications and Future Directions

The updated IPDAS 5.0 standards carry significant clinical implications for healthcare professionals and organizations committed to shared decision-making. By providing a more robust and comprehensive framework, IPDAS 5.0 enables clinicians to more effectively evaluate and select high-quality PDAs for their patients. The enhanced criteria for digital PDAs are particularly relevant in an increasingly digitized healthcare landscape, offering guidance on features such as interactivity, data security, and integration with electronic health records. Furthermore, the explicit focus on health equity and cultural appropriateness encourages the development and deployment of PDAs that are accessible and relevant to diverse patient populations, thereby reducing disparities in care.

For developers of patient decision aids, IPDAS 5.0 serves as an essential blueprint for creating tools that are not only evidence-based but also user-centered and impactful. Adherence to these standards can lead to PDAs that genuinely empower patients to make informed choices aligned with their values, ultimately improving patient satisfaction and health outcomes. The emphasis on implementation criteria also highlights the importance of integrating PDAs seamlessly into clinical workflows, ensuring they are readily available and utilized at appropriate points in the care journey.

While IPDAS 5.0 represents a substantial advancement, ongoing research and iterative refinement will remain crucial. Future directions may include exploring the impact of artificial intelligence and machine learning in PDA development, further integrating patient-reported outcome measures into PDA evaluation, and developing tailored implementation strategies for various clinical settings and patient groups. The IPDAS Collaboration's commitment to continuous improvement ensures that the standards will evolve alongside advancements in medical science and digital health, continuing to champion high-quality shared decision-making for all patients.

CLINICAL IMPLICATIONS

The release of IPDAS 5.0 marks a maturation of the patient decision aid field, moving beyond simply providing information to actively supporting the shared decision-making process. For clinicians, this means a clearer benchmark for evaluating the quality of PDAs they might recommend to patients. No longer is it sufficient for a tool to merely list pros and cons; the new standards demand evidence of systematic development, user testing, and consideration for health equity. This should prompt a critical review of currently used resources and a preference for aids that explicitly state their adherence to IPDAS 5.0 criteria. The onus is now on developers to meet these higher standards, and on clinicians to demand them.

From an industry perspective, particularly for pharmaceutical companies and medical device manufacturers who often develop patient education materials, IPDAS 5.0 presents a challenge and an opportunity. Materials that do not meet these updated standards risk being perceived as less credible or less effective in facilitating truly informed patient choices. Investing in the rigorous development and validation of PDAs according to IPDAS 5.0 could become a differentiator, demonstrating a commitment to patient-centered care beyond mere regulatory compliance. This could also influence the integration of PDAs into electronic health records and other digital health platforms, as adherence to these standards may become a de facto requirement for interoperability and clinical utility.

For patients, the updated IPDAS standards should translate into more reliable, comprehensive, and user-friendly decision aids. The emphasis on health equity and cultural appropriateness is particularly important, as it aims to ensure that PDAs are relevant and accessible to diverse patient populations, reducing disparities in informed decision-making. Patients should feel empowered to ask their healthcare providers about the quality of decision aids offered, and whether they meet recognized international standards. Ultimately, IPDAS 5.0 reinforces the principle that patient autonomy in healthcare decisions is best supported by high-quality, evidence-based tools that are developed with patient needs at their core.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Stacey D, Volk RJ, et al. The International Patient Decision Aid Standards (IPDAS) Collaboration: Evidence Update 2.0. Medical Decision Making. 2021;41(7):729-733. doi:10.1177/0272989X211035681
2. 2. Witteman HO, Maki KG, Vaisson G, Finderup J, Lewis KB, Dahl Steffensen K, et al. Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration. Medical Decision Making. 2021;41(7):736-754. doi:10.1177/0272989X211014163
3. 3. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333(7565):417. doi:10.1136/bmj.38926.629329.AE
4. 4. Stacey D, Legare F, Lewis KB, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2024;1(1):CD001431. doi:10.1002/14651858.CD001431.pub6

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com